评估RC288治疗实体瘤安全性和有效性的I/II期临床研究
一项多中心I/II期临床研究,旨在评估注射用RC288治疗局部晚期不可切除或转移性恶性实体瘤的安全性和有效性。
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Heping Liu
- 电话号码:+8610-65384976
- 邮箱:heping.liu@remegen.com
学习地点
-
-
Changsha
-
Hunan、Changsha、中国
- 尚未招聘
- Hunan Cancer Hospital
-
接触:
- Lin Wu
-
-
Chengdu
-
Sichuan、Chengdu、中国
- 尚未招聘
- Sichuan Cancer Hospital & Institute
-
接触:
- Huangming Hong
-
-
Fuzhou
-
Fujian、Fuzhou、中国
- 尚未招聘
- Fujian Cancer Hospital
-
接触:
- Zhangzhou Huang
-
Fujian、Fuzhou、中国
- 尚未招聘
- Fujian Medical University Union Hospital
-
接触:
- Jinhuo Lai
-
-
Guangzhou
-
Guangdong、Guangzhou、中国
- 尚未招聘
- Sun Yat sen University Cancer Center
-
接触:
- Yanxia Shi
-
接触:
- Yonghong Li
-
-
Guiyang
-
Guizhou、Guiyang、中国
- 尚未招聘
- The Affiliated Hospital of Guizhou Medical University
-
接触:
- Huixin Ge
-
-
Haerbin
-
Heilongjiang、Haerbin、中国
- 尚未招聘
- Harbin Medical University Cancer Hospital
-
接触:
- Baogang Liu
-
-
Hunan
-
Changsha、Hunan、中国
- 招聘中
- Hunan Cancer Hospital
-
接触:
- Weiqing Han
- 电话号码:+86731-89762271
- 邮箱:md70210@sina.com
-
-
Jiangsu
-
Nanjing、Jiangsu、中国
- 招聘中
- Nanjing Drum Tower Hospital
-
-
Jinan
-
Shandong、Jinan、中国
- 尚未招聘
- Cancer Hospital of Shandong First Medical University Cancer Hospital
-
接触:
- Juan Li
-
接触:
- Benkui Zou
-
Shandong、Jinan、中国
- 招聘中
- Shanxi Cancer Hospital
-
-
Shanxi
-
Shanxi、Shanxi、中国
- 招聘中
- Shanxi Cancer Hospital
-
-
Taizhou
-
Zhejiang、Taizhou、中国
- 尚未招聘
- Taizhou Hospital of Zhejiang Province
-
-
Wenzhou
-
Zhejiang、Wenzhou、中国
- 尚未招聘
- The First Affiliated Hospital of Wenzhou Medical University
-
接触:
- Wei Chen
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Voluntarily participate in this study, sign the informed consent form, and be able to adhere to the study protocol;
- Age between 18 and 75 years (including 18 and 75 years);
- ECOG PS score of 0 or 1;
- Expected survival ≥12 weeks;
- According to RECIST v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion;
- Sufficient bone marrow, liver, kidney, and blood clotting function
Exclusion Criteria:
- Pregnant, breastfeeding, or intending to become pregnant subjects.
- Subjects with brain metastases.
- Subjects with unresolved toxicities from prior anti-tumor therapy not recovered to NCI-CTCAE v6.0 Grade 1.
- Subjects with known hypersensitivity or delayed allergic reactions to any component of the investigational drug or similar drugs.
- Subjects with acute, chronic, or symptomatic infections.
- Subjects with uncontrolled cardiovascular diseases.
- Subjects with confirmed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severely impaired pulmonary function, or other pulmonary diseases.
- History of underlying pulmonary disease.
- Subjects with a history of cirrhosis (Child-Pugh B or C class).
- Clinically significant gastrointestinal disease.
- Subjects with uncontrolled diabetes (HbA1c ≥ 10%).
- Occurrence of hemorrhagic events of Grade ≥2 per NCI CTCAE (v6.0) within 4 weeks prior to screening; or clinical manifestations suggestive of a significant bleeding tendency within 4 weeks prior to screening.
- Imaging during the screening period shows tumor invasion or involvement of vital organs, with imaging evidence judged by the investigator to indicate a risk of bleeding or fistula formation.
- History of arterial/venous thromboembolic events within 6 months prior to the first dose.
- Presence of pericardial effusion or cardiac tamponade, or third-space fluid accumulation that, in the investigator's judgment, cannot be stably controlled by drainage or other methods.
- History of active autoimmune disease requiring systemic therapy within the past 2 years.
- History of other invasive malignancies within 5 years prior to the first dose, or evidence of residual disease from any previously diagnosed malignancy.
- History of other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
- History of or current poorly controlled psychiatric disorder.
- Poor compliance, and patients who are expected to be unable to cooperate with the completion of trial procedures.
- Presence of any other disease, metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, gives reasonable suspicion of a condition that contraindicates the use of the investigational drug, may affect the interpretation of study results, or places the patient at high risk.
- Local or systemic diseases not caused by malignancy, or diseases or symptoms secondary to the tumor, which may lead to higher medical risks and/or uncertainty in survival assessment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RC288 (Phase I, dose escalation)
There are six predefined escalating dose levels. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
|
实验性的:RC288 (Phase II, dose expansion)
In the multi-indication cohort expansion phase, further assess the efficacy and safety of RC288 in various cancer types using the RP2D. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
剂量限制性毒性 (DLT)
大体时间:24个月
|
24个月
|
|
不良事件/严重不良事件的发生率和严重程度(根据NCI CTCAE v6.0分级)
大体时间:24个月
|
24个月
|
|
确定RC288的RP2D
大体时间:24个月
|
24个月
|
|
MTD 和/或 MAD
大体时间:24个月
|
24个月
|
|
前列腺癌队列:研究者根据RECIST v1.1标准和PCWG3标准评估的客观缓解率
大体时间:24个月
|
24个月
|
|
非前列腺癌队列:研究者根据RECIST v1.1标准评估的客观缓解率
大体时间:24个月
|
24个月
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.